Moreover, findings from experiments involving RBD-mediated cardiopulmonary injury suggest that blockade of the interaction between SARS-CoV-2 RBD protein and hACE2 may represent a novel treatment strategy for COVID-19 beyond the current focus weighted toward S1 protein. Here, PSMD1 is linked to COVID-19.